As suggested by proteomics, the major effect from losartan treatment of RDEB model mice was reduction of inflammation; lower tissue inflammation and lower levels of circulating IL-6 and TGFβ correlated with milder disease. This evidence concerns the gene TGFB1 and recessive dystrophic epidermolysis bullosa.